PEN Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 12.1% compared to Penumbra's net margin of 14.45%. Penumbra's return on equity of 3.62% beat Boston Scientific's return on equity of 9.57%.

Penumbra has a consensus price target of $318.63, signalling upside risk potential of 16.87%. On the other hand Boston Scientific has an analysts' consensus of $116.96 which suggests that it could grow by 10.17%. Given that Penumbra has higher upside potential than Boston Scientific, analysts believe Penumbra is more attractive than Boston Scientific.

Penumbra has a beta of 0.528, which suggesting that the stock is 47.181% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Penumbra's net income of $39.2M is lower than Boston Scientific's net income of $674M. Notably, Penumbra's price-to-earnings ratio is 257.20x while Boston Scientific's PE ratio is 77.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.69x versus 9.00x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

ICU Medical has a net margin of 12.1% compared to Penumbra's net margin of -2.56%. Penumbra's return on equity of 3.62% beat ICU Medical's return on equity of -4.64%.

Penumbra has a consensus price target of $318.63, signalling upside risk potential of 16.87%. On the other hand ICU Medical has an analysts' consensus of $186.20 which suggests that it could grow by 42.75%. Given that ICU Medical has higher upside potential than Penumbra, analysts believe ICU Medical is more attractive than Penumbra.

Penumbra has a beta of 0.528, which suggesting that the stock is 47.181% less volatile than S&P 500. In comparison ICU Medical has a beta of 0.870, suggesting its less volatile than the S&P 500 by 12.976%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. ICU Medical pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than ICU Medical quarterly revenues of $604.7M. Penumbra's net income of $39.2M is higher than ICU Medical's net income of -$15.5M. Notably, Penumbra's price-to-earnings ratio is 257.20x while ICU Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.69x versus 1.32x for ICU Medical. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 12.1% compared to Penumbra's net margin of 30.99%. Penumbra's return on equity of 3.62% beat Intuitive Surgical's return on equity of 15.82%.

Penumbra has a consensus price target of $318.63, signalling upside risk potential of 16.87%. On the other hand Intuitive Surgical has an analysts' consensus of $575.78 which suggests that it could grow by 4.65%. Given that Penumbra has higher upside potential than Intuitive Surgical, analysts believe Penumbra is more attractive than Intuitive Surgical.

Penumbra has a beta of 0.528, which suggesting that the stock is 47.181% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.708%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Penumbra's net income of $39.2M is lower than Intuitive Surgical's net income of $698.4M. Notably, Penumbra's price-to-earnings ratio is 257.20x while Intuitive Surgical's PE ratio is 80.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.69x versus 22.92x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of 12.1% compared to Penumbra's net margin of 8.48%. Penumbra's return on equity of 3.62% beat Merit Medical Systems's return on equity of 9.19%.

Penumbra has a consensus price target of $318.63, signalling upside risk potential of 16.87%. On the other hand Merit Medical Systems has an analysts' consensus of $108.55 which suggests that it could grow by 12.48%. Given that Penumbra has higher upside potential than Merit Medical Systems, analysts believe Penumbra is more attractive than Merit Medical Systems.

Penumbra has a beta of 0.528, which suggesting that the stock is 47.181% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.439%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than Merit Medical Systems quarterly revenues of $355.4M. Penumbra's net income of $39.2M is higher than Merit Medical Systems's net income of $30.1M. Notably, Penumbra's price-to-earnings ratio is 257.20x while Merit Medical Systems's PE ratio is 47.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.69x versus 4.17x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.